Adaptive Biotechnologies (ADPT) Expected to Announce Quarterly Earnings on Thursday

Adaptive Biotechnologies (NASDAQ:ADPT) will likely be announcing its Q4 2025 results after the market closes on Thursday, February 5th. Analysts expect the company to announce earnings of ($0.19) per share and revenue of $59.3830 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 5, 2026 at 4:30 PM ET.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its earnings results on Wednesday, November 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.01. The company had revenue of $93.97 million for the quarter, compared to analyst estimates of $58.76 million. Adaptive Biotechnologies had a negative net margin of 31.50% and a negative return on equity of 58.40%. The company’s revenue for the quarter was up 102.4% on a year-over-year basis. During the same quarter last year, the firm earned ($0.22) EPS. On average, analysts expect Adaptive Biotechnologies to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Adaptive Biotechnologies Stock Down 3.8%

ADPT stock opened at $18.50 on Thursday. Adaptive Biotechnologies has a twelve month low of $6.26 and a twelve month high of $20.76. The company has a market cap of $2.82 billion, a P/E ratio of -34.26 and a beta of 2.18. The business’s fifty day moving average is $17.26 and its 200-day moving average is $14.90.

Analysts Set New Price Targets

Several equities research analysts have issued reports on ADPT shares. Morgan Stanley started coverage on Adaptive Biotechnologies in a report on Monday, December 1st. They issued an “equal weight” rating and a $21.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, January 21st. BTIG Research raised their target price on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. TD Cowen reaffirmed a “buy” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, January 7th. Finally, Wall Street Zen upgraded shares of Adaptive Biotechnologies from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Adaptive Biotechnologies currently has a consensus rating of “Moderate Buy” and an average target price of $17.22.

Insider Buying and Selling at Adaptive Biotechnologies

In related news, CFO Kyle Piskel sold 162,820 shares of the business’s stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $19.50, for a total value of $3,174,990.00. Following the completion of the sale, the chief financial officer directly owned 216,637 shares in the company, valued at approximately $4,224,421.50. The trade was a 42.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Sharon Benzeno sold 308,477 shares of the stock in a transaction that occurred on Friday, November 21st. The stock was sold at an average price of $16.91, for a total transaction of $5,216,346.07. Following the sale, the insider owned 296,791 shares in the company, valued at $5,018,735.81. This represents a 50.97% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 1,442,530 shares of company stock valued at $24,610,748 in the last three months. Corporate insiders own 6.40% of the company’s stock.

Hedge Funds Weigh In On Adaptive Biotechnologies

Several large investors have recently modified their holdings of the business. California State Teachers Retirement System raised its position in shares of Adaptive Biotechnologies by 1.0% during the second quarter. California State Teachers Retirement System now owns 98,321 shares of the company’s stock worth $1,145,000 after acquiring an additional 933 shares during the last quarter. Captrust Financial Advisors boosted its holdings in Adaptive Biotechnologies by 7.6% in the second quarter. Captrust Financial Advisors now owns 15,762 shares of the company’s stock worth $184,000 after acquiring an additional 1,119 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Adaptive Biotechnologies by 4.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company’s stock valued at $511,000 after purchasing an additional 2,914 shares during the period. Alliancebernstein L.P. grew its holdings in shares of Adaptive Biotechnologies by 2.7% during the third quarter. Alliancebernstein L.P. now owns 156,290 shares of the company’s stock valued at $2,338,000 after buying an additional 4,100 shares during the last quarter. Finally, CANADA LIFE ASSURANCE Co boosted its stake in Adaptive Biotechnologies by 17.6% during the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 30,469 shares of the company’s stock valued at $456,000 after purchasing an additional 4,552 shares during the last quarter. Institutional investors own 99.17% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.